Pura Vida Investments’s Intellia Therapeutics NTLA Stock Holding History

Pura Vida Investments’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-50,000	Closed	-$2.59M	–	235
2022 Q2	$2.59M	Buy	+50,000	New	+$2.54M	0.15%	126
2021 Q4	–	Sell	-95,700	Closed	-$12.8M	–	288
2021 Q3	$12.8M	Sell	95,700 -206,700	-68%	-$31.3M	0.39%	65
2021 Q2	$49M	Buy	302,400 +104,100	+52%	+$8.11M	1.52%	12
2021 Q1	$15.9M	Buy	+198,300	New	+$13.3M	0.45%	44

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Pura Vida Investments's NTLA Position: Q2 2022 in Review

Pura Vida Investments sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 104,073 shares — an estimated $5.28M sold.

Pura Vida Investments first reported a position in NTLA in Q1 2021 and held it in 5 quarters. The position peaked at $34.8M in Q2 2021. 300 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

Pura Vida Investments reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
Pura Vida Investments sold 104,073 Intellia Therapeutics shares in Q2 2022, an estimated $5.28M.
Pura Vida Investments first reported a position in Intellia Therapeutics in Q1 2021 and held it in 5 quarters.
Pura Vida Investments's Intellia Therapeutics position peaked at $34.8M in Q2 2021.
300 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.